<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vinblastine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vinblastine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Vinblastine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10044" href="/d/html/10044.html" rel="external">see "Vinblastine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11530" href="/d/html/11530.html" rel="external">see "Vinblastine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708853"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">This preparation should be administered by individuals experienced in the administration of vinblastine sulfate. </p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Extravasation: </span>
<div class="collapsible-wrap">
<p style="text-indent:0em;"> It is extremely important that the intravenous needle or catheter be properly positioned before any vinblastine sulfate is injected. Leakage into surrounding tissue during intravenous administration of vinblastine may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Appropriate administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">For intravenous use only - fatal if given by other routes.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1050585"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Antimicrotubular</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Mitotic Inhibitor</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Vinca Alkaloid</span></li></ul></div>
<div class="block dop drugH1Div" id="F234123"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>For IV use only; </b>
<b>fatal if administered by other routes<b>.</b></b> In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (<b>NOT</b> a syringe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020'])">Ref</a></span>). Dosing and frequency may vary by indication, protocol, and/or treatment phase and hematologic response; refer to specific protocol.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b4c0473-1817-4b8c-9c79-296fb24a87f0">Glioma, low-grade</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glioma, low-grade: </b>Limited data available: Infants ≥8 months, Children, and Adolescents: IV: 6 mg/m<sup>2</sup>/dose every 7 days for 70 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27573663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27573663'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:4em;">ABVD regimen: 6 mg/m<sup>2</sup>/dose administered on days 1 and 15 of a 28-day cycle in combination with doxorubicin, bleomycin, and dacarbazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9508171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9508171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">ChIVPP regimen: 6 mg/m<sup>2</sup>/dose administered on days 1 and 8 of a 28-day cycle in combination with chlorambucil, procarbazine, and prednisolone; minimum reported age: 7 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12437639','lexi-content-ref-17379506','lexi-content-ref-17760808','lexi-content-ref-17509875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12437639','lexi-content-ref-17379506','lexi-content-ref-17760808','lexi-content-ref-17509875'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f255b0ca-652b-494f-be40-1bf06deab9bd">Langerhans cell histiocytosis; multisystem</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Langerhans cell histiocytosis; multisystem (Letterer-Siwe disease; Histiocytosis X):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Induction: 6 mg/m<sup>2</sup>/dose every 7 days in combination with prednisone for 6 to 12 weeks depending upon clinical response; then begin maintenance therapy of 6 mg/m<sup>2</sup>/dose every 3 weeks in combination with prednisone, continue for a total duration of vinblastine therapy of 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23589673','lexi-content-ref-23109216']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23589673','lexi-content-ref-23109216'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ee47ba0-ffff-4b0a-a9ff-87c4f409f994">Neuroblastoma, recurrent or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, recurrent or refractory: </b>Limited data available: Children and Adolescents: IV: 3 mg/m<sup>2</sup>/dose every 14 days; as metronomic therapy in combination with celecoxib, cyclophosphamide, and etoposide for up to 24 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29148865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29148865'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193268"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block dohp drugH1Div" id="F51193269"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">All patients: The manufacturer's labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have also been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644','lexi-content-ref-17914077'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin &gt;3 times ULN: Avoid use.</p></div>
<div class="block doa drugH1Div" id="F234102"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10044" href="/d/html/10044.html" rel="external">see "Vinblastine: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>For IV use only; fatal if administered by other routes. </b>The Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag and <b>NOT</b> in a syringe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3810c766-bd22-4b38-a74f-83d570ec742e">Bladder cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer </b>
<b>(off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Locally advanced or metastatic disease:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Dose-dense MVAC regimen: <b>IV:</b> 3 mg/m<sup>2</sup> on day 2 every 14 days (in combination with methotrexate, doxorubicin, cisplatin, and growth factor support) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11352955','lexi-content-ref-16330205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11352955','lexi-content-ref-16330205'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">MVAC regimen: <b>IV: </b>3 mg/m<sup>2</sup> on days 2, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, and cisplatin) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11001674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11001674'])">Ref</a></span>) <b>or</b> 3 mg/m<sup>2</sup> on days 2, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, and cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11352955','lexi-content-ref-16330205']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11352955','lexi-content-ref-16330205'])">Ref</a></span>) <b>or</b> 3 mg/m<sup>2</sup> on days 1, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, cisplatin, and filgrastim) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14665607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14665607'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Neoadjuvant treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Patients with non–organ-confined disease at cystectomy who did not receive cisplatin-based neoadjuvant chemotherapy should be offered an adjuvant cisplatin-based chemotherapy regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28456635']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28456635'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dose-dense MVAC regimen: <b>IV: </b>3 mg/m<sup>2</sup> on day 1 or 2 every 14 days (in combination with methotrexate, doxorubicin, cisplatin, and pegfilgrastim) for 3 to 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24821883','lexi-content-ref-24821881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24821883','lexi-content-ref-24821881'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">MVAC regimen: <b>IV: </b>3 mg/m<sup>2</sup> on days 2, 15, and 22 every 28 days (in combination with methotrexate, doxorubicin, and cisplatin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12944571']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12944571'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CMV regimen: <b>IV: </b>4 mg/m<sup>2</sup> on days 1 and 8 every 21 days (in combination with methotrexate, cisplatin, and leucovorin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21502557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21502557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">ABVD regimen:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Favorable/early stage disease: </i>
<b>IV: </b>6 mg/m<sup>2</sup> on days 1 and 15 of a 28-day cycle (in combination with doxorubicin, bleomycin, dacarbazine, and radiation therapy) for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17606976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17606976'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Unfavorable/early stage disease</i>: <b>IV: </b>6 mg/m<sup>2</sup> on days 1 and 15 of a 28-day cycle (in combination with doxorubicin, bleomycin, dacarbazine, and radiation therapy) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20713848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20713848'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Unfavorable/advanced stage disease:</i>
<b>IV: </b>6 mg/m<sup>2</sup> on days 1 and 15 of a 28-day cycle (in combination with doxorubicin, bleomycin, dacarbazine, and radiation therapy) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1383821','lexi-content-ref-23182987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1383821','lexi-content-ref-23182987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Stanford V regimen:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Favorable/early stage disease:</i>
<b>IV: </b>6 mg/m<sup>2</sup> in weeks 1, 3, 5, and 7 (in combination with doxorubicin, mechlorethamine, vincristine, bleomycin, etoposide, prednisone, and radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23136225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23136225'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Unfavorable/advanced stage disease: </i>
<b>IV: </b>6 mg/m<sup>2</sup> in weeks 1, 3, 5, 7, 9, and 11 (in combination with doxorubicin, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7537796','lexi-content-ref-23182987','lexi-content-ref-11821442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7537796','lexi-content-ref-23182987','lexi-content-ref-11821442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">VEPEMB regimen: Adults ≥60 years of age: <b>IV: </b>6 mg/m<sup>2</sup> on day 1 of each 28-day cycle (in combination with cyclophosphamide, prednisone/prednisolone, procarbazine, etoposide, mitoxantrone, and bleomycin, ± radiation therapy) for 3 cycles (stage 1A or IIA disease) or for 6 cycles (stage IIB, III, or IV disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14679131','lexi-content-ref-22577177']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14679131','lexi-content-ref-22577177'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="16bc2e4e-f9f5-43de-8127-78c828046d85">Kaposi sarcoma, oral lesions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kaposi sarcoma, oral lesions (off-label route; based on limited data):</b>
<b>Intralesional:</b> 0.1 mL per 0.5 cm<sup>2</sup> lesion injected directly into the lesion (a 0.2 mg/mL vinblastine solution was used). Larger lesions may require multiple injections; reported range of volume injected: 0.8 to 4 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8448735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8448735'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c818fdd2-0859-4362-9aae-976c7de99cda">Non–small cell lung cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment after complete resection: <b>IV: </b>4 mg/m<sup>2</sup> on days 1, 8, 15, 22, and 29, then every 2 weeks (in combination with cisplatin) until last cisplatin dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14736927']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14736927'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Concurrent radiation: <b>IV: </b>5 mg/m<sup>2</sup> on days 1, 8, 15, 22, and 29 (in combination with cisplatin and concurrent radiation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21903745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21903745'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7010e3ba-7b4f-4a1f-86d7-7a0447b9278e">Soft tissue sarcoma, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Soft tissue sarcoma (desmoid tumors, aggressive fibromatosis), advanced (off-label use):</b>
<b>IV:</b> 6 mg/m<sup>2</sup> every 7 to 10 days (dose usually rounded to 10 mg) in combination with methotrexate for 1 year (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11571741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11571741'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fffdbf1f-e052-42f2-a151-e1f8a98e129a">Testicular cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer (off-label dosing):</b> VeIP regimen: <b>IV:</b> 0.11 mg/kg daily for 2 days every 21 days (in combination with ifosfamide, cisplatin, and mesna) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9667270','lexi-content-ref-Loehrer.1','lexi-content-ref-2844110']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9667270','lexi-content-ref-Loehrer.1','lexi-content-ref-2844110'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Manufacturer's labeling:</b></i>
<b>
<b>Hodgkin lymphoma, non-Hodgkin lymphomas (lymphocytic lymphoma, histiocytic lymphoma, advanced mycosis fungoides), testicular cancer, Kaposi sarcoma, Langerhans cell histiocytosis (histiocytosis X, Letterer-Siwe disease):</b></b> Dosing in the prescribing information may not reflect current clinical practice. <b>IV:</b> 3.7 mg/m<sup>2</sup>; adjust dose every 7 days (based on white blood cell response) up to 5.5 mg/m<sup>2</sup> (second dose); 7.4 mg/m<sup>2</sup> (third dose); 9.25 mg/m<sup>2</sup> (fourth dose); and 11.1 mg/m<sup>2</sup> (fifth dose); do not administer more frequently than every 7 days. Usual dosage range: 5.5 to 7.4 mg/m<sup>2</sup> every 7 days; Maximum dose: 18.5 mg/m<sup>2</sup>; dosage adjustment goal is to reduce white blood cell count to ~3,000/mm<sup>3</sup>. Frequency and duration of therapy may vary by indication, concomitant combination chemotherapy and hematologic response.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991042"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50988274"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Toxicity may be increased in patients with hepatic dysfunction. The manufacturer's labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of dose</p>
<p style="text-indent:-2em;margin-left:2em;">The following adjustments have also been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644','lexi-content-ref-17914077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644','lexi-content-ref-17914077'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose</p>
<p style="text-indent:-2em;margin-left:4em;">Serum bilirubin &gt;3 times ULN: Avoid use.</p></div>
<div class="block adr drugH1Div" id="F234071"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Angina pectoris, cerebrovascular accident, ECG abnormality, hypertension (common), ischemic heart disease, limb ischemia, myocardial infarction, Raynaud's phenomenon</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Decreased deep tendon reflex, depression, dizziness, headache, malaise (common), metallic taste, neurotoxicity (duration: &gt;24 hours), paresthesia, peripheral neuritis, seizure, tumor pain (common), vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Alopecia (common), dermatitis, skin blister, skin photosensitivity (rare), skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hyperuricemia, SIADH (syndrome of inappropriate antidiuretic hormone secretion)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal pain, anorexia, constipation (common), diarrhea, enterocolitis (hemorrhagic), gastrointestinal hemorrhage, intestinal obstruction, nausea (mild), paralytic ileus, stomatitis, toxic megacolon, vomiting (mild)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Azoospermia, urinary retention</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Anemia, bone marrow depression (common), granulocytopenia (common; nadir: 5 to 10 days; recovery: 7 to 14 days; dose-limiting toxicity), hemolytic uremic syndrome, leukopenia (common; nadir: 5 to 10 days; recovery: 7 to 14 days; dose-limiting toxicity), rectal hemorrhage, thrombocytopenia (recovery within a few days), thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Local irritation</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Jaw pain (common), myalgia, ostealgia (common), weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Nystagmus</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Auditory disturbance, deafness, vestibular disturbance</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Bronchospasm, dyspnea, pharyngitis</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Radiation recall phenomenon</p></div>
<div class="block coi drugH1Div" id="F234085"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Significant granulocytopenia (unless as a result of condition being treated); presence of bacterial infection</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications not in the US labeling: Pregnancy</p></div>
<div class="block war drugH1Div" id="F234068"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Leukopenia commonly occurs; granulocytopenia may be severe with higher doses. The leukocyte nadir generally occurs 5 to 10 days after administration; recovery typically occurs 7 to 14 days later. Leukopenia may be more pronounced in cachectic patients and patients with skin ulceration and may be less pronounced with lower doses used for maintenance therapy. Leukocytes and platelets may fall considerably with moderate doses when marrow is infiltrated with malignant cells (further use in this situation is not recommended). Thrombocytopenia and anemia may occur rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Vinblastine is a vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Extravasation may cause significant irritation. Individuals administering should be experienced in vinblastine administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal toxicity: Stomatitis may occur (rare); may be disabling, but is usually reversible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neurotoxicity: May rarely cause disabling neurotoxicity; usually reversible. Seizures and severe and permanent CNS damage have occurred with higher than recommended doses and/or when administered more frequently than recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Acute shortness of breath and severe bronchospasm have been reported, most often in association with concurrent administration of mitomycin; may occur within minutes to several hours following vinblastine administration or up to 14 days following mitomycin administration; use caution in patients with preexisting pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Ischemic heart disease: Use with caution in patients with ischemic heart disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• NOT for intrathecal use:<b> For IV use only. Administration by other routes may result in death.</b> To prevent administration errors, the Institute for Safe Medication Practices (ISMP) Targeted Medication Safety Best Practices for Hospitals initiative strongly recommends dispensing vinblastine diluted in a minibag (ISMP 2020). Vinblastine should <b>NOT</b> be prepared during the preparation of any medications intended for CNS administration. After preparation, keep vinblastine in a location <b>away</b> from the separate storage location recommended for medications intended for CNS administration. Vinblastine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for CNS administration (ASCO/ONS [Neuss 2016]). Refer to vinblastine manufacturer labeling for information regarding management of inadvertent intrathecal vinblastine exposure.</p></div>
<div class="block foc drugH1Div" id="F234079"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F234064"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16324092"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (vinBLAStine Sulfate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/mL (per mL): $6.45</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868603"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (10 mL, 13.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as sulfate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52614008"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b> In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (NOT in a syringe) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020'])">Ref</a></span>)</b>.</p>
<p style="text-indent:-2em;margin-left:2em;">IV infusion: For IV administration only. <b>Fatal if given intrathecally.</b> The preferred administration is as a short infusion in a minibag. If administration via a minibag is not possible, vinblastine may also be administered undiluted (1 mg/mL) over 1 minute into a free flowing IV line to prevent venous irritation/extravasation. Prolonged administration times (≥30 to 60 minutes) and/or increased administration volumes may increase the risk of vein irritation and extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Remaining portion of the vinblastine dose should be infused through a separate vein.</p></div>
<div class="block adm drugH1Div" id="F234082"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b>
<b>The Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag and NOT in a syringe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ISMP.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ISMP.2020'])">Ref</a></span>).</b> For IV administration only. <b>Fatal if administered by other routes.</b> The preferred administration is as a short infusion in a 25 to 50 mL minibag. Prolonged administration times (≥30 to 60 minutes) and/or increased administration volumes may increase the risk of vein irritation and extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449'])">Ref</a></span>). Remaining portion of the vinblastine dose should be infused through a separate vein.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyaluronidase:</i> If needle/cannula still in place, administer 1 to 6 mL hyaluronidase (150 units/mL) into the existing IV line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22997449','lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22997449','lexi-content-ref-21255716'])">Ref</a></span>). If needle/cannula was removed, inject 1 to 6 mL (150 units/mL) subcutaneously in a clockwise manner using 1 mL for each 1 mL of drug extravasated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21255716']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21255716'])">Ref</a></span>) <b>or</b> administer 1 mL (150 units/mL) as 5 separate 0.2 mL injections (using a 25-gauge needle) subcutaneously into the extravasation site (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Polovich.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Polovich.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Intralesional (off-label route): Administer local anesthesia prior to vinblastine intralesional injections; analgesia may be required for 1 to 2 days following vinblastine administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8448735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8448735'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132729"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F234093"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">
<b>Note: Vinblastine should be dispensed in a minibag (ISMP 2020).</b></p>
<p style="text-indent:-2em;margin-left:2em;">Store intact vials at 2°C to 8°C (36°F to 46°F). Protect from light. Solutions diluted for infusion in NS, D5W, or LR (20 mcg/mL concentration) are stable for up to 21 days if protected from light (Beijnen 1989). The formulation of vinblastine may have changed since this stability study was conducted; consult the manufacturer's prescribing information for further information. Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>
<div class="block usep drugH1Div" id="F53569476"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of Hodgkin lymphoma, lymphocytic lymphoma, histiocytic lymphoma, testicular cancers, Langerhans cell histiocytosis (histiocytosis X; Letterer-Siwe disease), choriocarcinoma, mycosis fungoides, and Kaposi sarcoma (All indications: FDA approved in pediatrics [age not specified] and adults).</p></div>
<div class="block mst drugH1Div" id="F234153"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">VinBLAStine may be confused with vinCRIStine, vinorelbine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vinblastine is for IV administration only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, the ISMP strongly recommends that vinblastine doses be dispensed in a small minibag (25 to 50 mL of a compatible solution), and <b>NOT</b> a syringe (ISMP 2020). Vinblastine should <b>NOT </b>be prepared during the preparation of any medications intended for CNS administration. After preparation, keep vinblastine in a location <b>away</b> from the separate storage location recommended for medications intended for CNS administration. Vinblastine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for CNS administration.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F234139"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F234073"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Adenovirus Vector): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Adenovirus Vector).  Management: Administer a 2nd dose using an mRNA COVID-19 vaccine (at least 4 weeks after the primary vaccine dose) and a bivalent booster dose (at least 2 months after the additional mRNA dose or any other boosters).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Inactivated Virus): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Inactivated Virus). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (mRNA).  Management: Give a 3-dose primary series for all patients aged 6 months and older taking immunosuppressive medications or therapies. Booster doses are recommended for certain age groups. See CDC guidance for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Subunit): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Subunit). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (Virus-like Particles): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of COVID-19 Vaccine (Virus-like Particles). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of VinBLAStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of VinBLAStine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: VinBLAStine may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53044965"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who could become pregnant should avoid becoming pregnant during vinblastine treatment. Reversible amenorrhea may occur when vinblastine is used in some combination regimens (dose related). Aspermia has been reported in males who have received treatment with vinblastine.</p></div>
<div class="block pri drugH1Div" id="F6753821"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on placental perfusion studies, vinblastine is expected to cross the placenta (Sudhakaran 2008). Outcome information following maternal use of vinblastine as a single agent or as part of combination therapy during pregnancy is available (Avilés 2018; Eyre 2015).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology (ESMO) has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The ESMO guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]). An international consensus panel has published guidelines for hematologic malignancies during pregnancy. Vinblastine is a component of the ABVD regimen, which is used for the treatment of Hodgkin lymphoma. If treatment cannot be deferred until after delivery in patients with early stage Hodgkin lymphoma, ABVD may be administered safely and effectively in the latter phase of pregnancy (based on limited data); for patients with advanced-stage disease, ABVD can be administered in the second and third trimesters (Lishner 2016).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53569477"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count, serum uric acid, hepatic function tests.</p></div>
<div class="block pha drugH1Div" id="F234067"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Vinblastine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinblastine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>
<div class="block phk drugH1Div" id="F234084"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (via CYP3A) to active metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: ~25 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (10%); urine (14%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F234088"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Blastovin | Vinblastina filaxis | Vinblastina gobbi | Vinblastina kemex</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin | Vinblastine comp</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Vinblastin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblasin | Vinblastine teva | Vinblastine wyeth pharmaceutic</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin | Velbe | Vinblastin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Faulblastina | Rabinefil | Velban | Vinatin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lemblastine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Vinblastine | Vinblastine sulphate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Lemblastine | Velbe | Vinblastina | Vinblastina sulfato | Vincablas</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin | Vinblastinsulfat Teva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin | Vinblastine teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Velbastine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Vinblastina</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Velbastine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Trav vinblastine | Velbe | Vinblastine | Vinblastine tillot</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastine sulphate</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Vinblastin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Erbablas | Velbe | Vinblastine</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Vinblastine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Chemoblast | Cytoblastin | Uniblastin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastina teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin | Velbe</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Exal | Vinblastin kyorin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Velbastine | Vinblastin | Vinblastine sulfate pch</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Vinblastine sulphate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin | Uniblastin | Velbe | Vinblastine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin | Vinblastin-Teva | Vinblastine teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Okanavinblastin | Velbe</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Blestinib | Diranovyl | Lemblastine | Velbe | Vinblastina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin aqueous | Velbastine | Velbe | Vinblastine | Vinblastine sulphate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Blastivin | Velbe | Vinblastine | Vinblastinesulfaat PCH</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Vinblastin | Vinblastine</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Oncostin | Velbastine | Velbe</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Uniblastin | Velbe | Vinblastine | Vinko</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Velban</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Solblastin | Velbe</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Vinblastina kemex</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin | Vinblastina teva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastine | Vinblastin | Vinblastine lens | Vinblastine richter | Vinblastine teva</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastine sulphate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastine teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Vinblastin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Velvin | Vinblastine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Velbe | Vinblastin | Vinko</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Velbe</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Vinblastin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Vinblastina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cytoblastin aqueous | Periblastine | Velbe | Vinblastine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23136225">
<a name="23136225"></a>Advani RH, Hoppe RT, Baer D, et al. Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. <i>Ann Oncol</i>. 2013;24(4):1044-1048. doi:10.1093/annonc/mds542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23136225/pubmed" id="23136225" target="_blank">23136225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14736927">
<a name="14736927"></a>Arriagada R, Bergman B, Dunant A, et al. Cisplatin-Based Adjuvant Chemotherapy in Patients With Completely Resected Non-Small-Cell Lung Cancer. <i>N Engl J Med</i>. 2004;350(4):351-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/14736927/pubmed" id="14736927" target="_blank">14736927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19001327">
<a name="19001327"></a>Atkins MB, Hsu J, Lee S, et al; Eastern Cooperative Oncology Group. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. <i>J Clin Oncol</i>. 2008;26(35):5748-5754. doi:10.1200/JCO.2008.17.5448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/19001327/pubmed" id="19001327" target="_blank">19001327</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12437639">
<a name="12437639"></a>Atra A, Higgs E, Capra M, et al. ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies. <i>Br J Haematol</i>. 2002;119(3):647-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/12437639/pubmed" id="12437639" target="_blank">12437639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29326803">
<a name="29326803"></a>Avilés A, Nambo MJ, Neri N. Treatment of early stages Hodgkin lymphoma during pregnancy. <i>Mediterr J Hematol Infect Dis.</i> 2018;10(1):e2018006. doi:10.4084/MJHID.2018.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/29326803/pubmed" id="29326803" target="_blank">29326803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11571741">
<a name="11571741"></a>Azzarelli A, Gronchi A, Bertulli R, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis.. <i>Cancer</i>. 2001;92(5):1259-1264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11571741/pubmed" id="11571741" target="_blank">11571741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6189661">
<a name="6189661"></a>Balis FM, Holcenberg JS, Bleyer WA. Clinical Pharmacokinetics of Commonly Used Anticancer Drugs. <i>Clin Pharmacokinet</i>. 1983;8(3):202-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/6189661/pubmed" id="6189661" target="_blank">6189661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14665607">
<a name="14665607"></a>Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group [published correction appears in <i>J Clin Oncol</i>. 2004;22(9):1771]. <i>J Clin Oncol</i>. 2004;22(2):220-228.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/14665607/pubmed" id="14665607" target="_blank">14665607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7537796">
<a name="7537796"></a>Bartlett NL, Rosenberg SA, Hoppe RT, et al. Brief Chemotherapy, Stanford V, and Adjuvant Radiotherapy for Bulky or Advanced-Stage Hodgkin’s Disease: A Preliminary Report. <i>J Clin Oncol</i>. 1995;13(5):1080-1088.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/7537796/pubmed" id="7537796" target="_blank">7537796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16394890">
<a name="16394890"></a>Bashir H, Motl S, Metzger ML, et al. Itraconazole-Enhanced Chemotherapy Toxicity in a Patient With Hodgkin Lymphoma. <i>J Pediatr Hematol Oncol</i>. 2006;28(1):33-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/16394890/pubmed" id="16394890" target="_blank">16394890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2709240">
<a name="2709240"></a>Beijnen JH, Vendrig DE, Underberg WJ. Stability of vinca alkaloid anticancer drugs in three commonly used infusion fluids. <i>J Parenter Sci Technol</i>. 1989;43(2):84-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/2709240/pubmed" id="2709240" target="_blank">2709240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29148865">
<a name="29148865"></a>Berthold F, Hömberg M, Proleskovskaya I, et al. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. <i>Pediatr Hematol Oncol</i>. 2017;34(5):308-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/29148865/pubmed" id="29148865" target="_blank">29148865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1383821">
<a name="1383821"></a>Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. <i>N Engl J Med.</i> 1992;327(21):1478-1484. doi:10.1056/NEJM199211193272102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/1383821/pubmed" id="1383821" target="_blank">1383821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17379506">
<a name="17379506"></a>Capra M, Hewitt M, Radford M, et al. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial. <i>Eur J Cancer</i>. 2007;43(7):1171-1179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17379506/pubmed" id="17379506" target="_blank">17379506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28456635">
<a name="28456635"></a>Chang SS, Bochner BH, Chou R, et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline [published correction appears in <i>J Urol</i>. 2017;198(5):1175]. <i>J Urol</i>. 2017;198(3):552-559. doi:10.1016/j.juro.2017.04.086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/28456635/pubmed" id="28456635" target="_blank">28456635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821883">
<a name="24821883"></a>Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>J Clin Oncol</i>. 2014;32(18):1889-1894. doi:10.1200/JCO.2013.52.4785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/24821883/pubmed" id="24821883" target="_blank">24821883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3555940">
<a name="3555940"></a>Crom WR, Glynn-Barnhart AM, Rodman JH, et al. Pharmacokinetics of Anticancer Drugs in Children. <i>Clin Pharmacokinet</i>. 1987;12(3):168-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/3555940/pubmed" id="3555940" target="_blank">3555940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21903745">
<a name="21903745"></a>Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. <i>J Natl Cancer Inst</i>. 2011;103(19):1452-1460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/21903745/pubmed" id="21903745" target="_blank">21903745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20713848">
<a name="20713848"></a>Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. <i>J Clin Oncol</i>. 2010;28(27):4199-4206.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/20713848/pubmed" id="20713848" target="_blank">20713848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17606976">
<a name="17606976"></a>Engert A, Franklin J, Eich HT, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. <i>J Clin Oncol</i>. 2007;25(23):3495-3502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17606976/pubmed" id="17606976" target="_blank">17606976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8448735">
<a name="8448735"></a>Epstein JB. Treatment of oral Kaposi sarcoma with intralesional vinblastine. <i>Cancer</i>. 1993;71(5):1722-1725. doi:10.1002/1097-0142(19930301)71:5&lt;1722::aid-cncr2820710503&gt;3.0.co;2-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/8448735/pubmed" id="8448735" target="_blank">8448735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25684034">
<a name="25684034"></a>Eyre TA, Lau IJ, Mackillop L, et al. Management and controversies of classical Hodgkin lymphoma in pregnancy. <i>Br J Haematol</i>. 2015;169(5):613-630. doi:10.1111/bjh.13327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/25684034/pubmed" id="25684034" target="_blank">25684034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of Chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23589673">
<a name="23589673"></a>Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. <i>Blood</i>. 2013;121(25):5006-5014.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23589673/pubmed" id="23589673" target="_blank">23589673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11283126">
<a name="11283126"></a>Göbel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. <i>J Clin Oncol</i>. 2001;19(7):1943-1950.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11283126/pubmed" id="11283126" target="_blank">11283126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23182987">
<a name="23182987"></a>Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>J Clin Oncol</i>. 2013;31(6):684-691. doi:10.1200/JCO.2012.43.4803<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23182987/pubmed" id="23182987" target="_blank">23182987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502557">
<a name="21502557"></a>Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>J Clin Oncol</i>. 2011;29(16):2171-2177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/21502557/pubmed" id="21502557" target="_blank">21502557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12944571">
<a name="12944571"></a>Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced Bladder Cancer. <i>N Engl J Med</i>. 2003;349(9):859-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/12944571/pubmed" id="12944571" target="_blank">12944571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17760808">
<a name="17760808"></a>Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. <i>Br J Haematol</i>. 2007;138(6):761-768.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17760808/pubmed" id="17760808" target="_blank">17760808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109216">
<a name="23109216"></a>Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. <i>Pediatr Blood Cancer</i>. 2013;60(2):175-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23109216/pubmed" id="23109216" target="_blank">23109216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821442">
<a name="11821442"></a>Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin's Disease: Mature Results of a Prospective Clinical Trial. <i>J Clin Oncol</i>. 2002;20(3):630-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11821442/pubmed" id="11821442" target="_blank">11821442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9508171">
<a name="9508171"></a>Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. <i>J Clin Oncol</i>. 1998;16(3):897-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/9508171/pubmed" id="9508171" target="_blank">9508171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.2020">
<a name="ISMP.2020"></a>Institute for Safe Medicine Practices (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pdf. Published February 21, 2020. Accessed January 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18048825">
<a name="18048825"></a>Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. <i>J Clin Oncol</i>. 2007;25(34):5426-5434.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/18048825/pubmed" id="18048825" target="_blank">18048825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27573663">
<a name="27573663"></a>Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study. <i>J Clin Oncol</i>. 2016;34(29):3537-3543.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/27573663/pubmed" id="27573663" target="_blank">27573663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14679131">
<a name="14679131"></a>Levis A, Anselmo AP, Ambrosetti A, et al. VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. <i>Ann Oncol.</i> 2004;15(1):123-128. doi:10.1093/annonc/mdh012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/14679131/pubmed" id="14679131" target="_blank">14679131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol.</i> 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9667270">
<a name="9667270"></a>Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine Plus Ifosfamide Plus Cisplatin as Initial Salvage Therapy in Recurrent Germ Cell Tumor. <i>J Clin Oncol</i>. 1998;16(7):2500-2504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/9667270/pubmed" id="9667270" target="_blank">9667270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2844110">
<a name="2844110"></a>Loehrer PJ Sr, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. <i>Ann Intern Med</i>. 1988;109(7):540-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/2844110/pubmed" id="2844110" target="_blank">2844110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Loehrer.1">
<a name="Loehrer.1"></a>Loehrer PJ Sr. Correction: Incomplete Dosage Information in Article on Germ Cell Cancer. <i>Ann Intern Med</i>. 1988;109(10):846.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19164215">
<a name="19164215"></a>Lopes LF, Macedo CR, Pontes EM, et al. Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. <i>J Clin Oncol</i>. 2009;27(8):1297-1303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/19164215/pubmed" id="19164215" target="_blank">19164215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27868581">
<a name="27868581"></a>Neuss MN, Gilmore TR, Belderson KM, et al. 2016 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards, including standards for pediatric oncology. <i>J Oncol Pract</i>. 2016;12(12):1262-1271. doi:10.1200/JOP.2016.017905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/27868581/pubmed" id="27868581" target="_blank">27868581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi: 10.1093/annonc/mdt199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Perez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):vii167-vii173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24821881">
<a name="24821881"></a>Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. <i>J Clin Oncol</i>. 2014;32(18):1895-1901. doi:10.1200/JCO.2013.53.2465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/24821881/pubmed" id="24821881" target="_blank">24821881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polovich.1">
<a name="Polovich.1"></a>Polovich M, Whitford JN, Olsen M. <i>Chemotherapy and Biotherapy Guidelines and Recommendations for Practice</i>, 3rd ed. Pittsburgh, PA: Oncology Nursing Society; 2009.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22577177">
<a name="22577177"></a>Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. <i>Blood</i>. 2012;119(25):6005-6015. doi:10.1182/blood-2011-12-396556<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/22577177/pubmed" id="22577177" target="_blank">22577177</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schneider DT, Calaminus G, Reinhard H, et al. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. <i>J Clin Oncol</i>. 2000;18(4):832-839.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21255716">
<a name="21255716"></a>Schulmeister L. Extravasation management: clinical update. <i>Semin Oncol Nurs</i>. 2011;27(1):82-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/21255716/pubmed" id="21255716" target="_blank">21255716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11352955">
<a name="11352955"></a>Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic M-VAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. <i>J Clin Oncol</i>. 2001;19(10):2638-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11352955/pubmed" id="11352955" target="_blank">11352955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16330205">
<a name="16330205"></a>Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. <i>Eur J Cancer</i>. 2006;42(1):50-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/16330205/pubmed" id="16330205" target="_blank">16330205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17509875">
<a name="17509875"></a>Stoneham S, Ashley S, Pinkerton R, et al. Hodgkin's lymphoma in children aged 5 years or less - the United Kingdom experience. <i>Eur J Cancer</i>. 2007;43(9):1415-1421.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17509875/pubmed" id="17509875" target="_blank">17509875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28170295">
<a name="28170295"></a>Stopenski S, Aslam A, Zhang X, et al. After chemotherapy treatment for maternal cancer during pregnancy, is breastfeeding possible? <i>Breastfeed Med.</i> 2017;12:91-97. doi:10.1089/bfm.2016.0166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/28170295/pubmed" id="28170295" target="_blank">28170295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18093255">
<a name="18093255"></a>Sudhakaran S, Rayner CR, Li J, Kong DC, et al. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus. <i>Br J Clin Pharmacol.</i> 2008;65(5):667-673. doi:10.1111/j.1365-2125.2007.03067.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/18093255/pubmed" id="18093255" target="_blank">18093255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17914077">
<a name="17914077"></a>Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary. <i>Oncologist</i>. 2007;12(9):1070-1083.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17914077/pubmed" id="17914077" target="_blank">17914077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25061513">
<a name="25061513"></a>Urbaniak C, McMillan A, Angelini M, et al. Effect of chemotherapy on the microbiota and metabolome of human milk, a case report. <i>Microbiome</i>. 2014;2:24. doi:10.1186/2049-2618-2-24<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/25061513/pubmed" id="25061513" target="_blank">25061513</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11001674">
<a name="11001674"></a>von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. <i>J Clin Oncol</i>. 2000;18(17):3068-3077.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11001674/pubmed" id="11001674" target="_blank">11001674</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Vinblastine Sulfate Injection (prescribing information). Lake Zurich, IL: Fresenius Kabi; November 2016.</div>
</li>
<li>
<div class="reference">
                  Vinblastine Sulfate Injection (product monograph). Kirkland, Quebec, Canada: Pfizer Canada ULC; April 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12881 Version 282.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
